Focused On-demand Library for Lysophosphatidic acid receptor 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P43657

UPID:

LPAR6_HUMAN

Alternative names:

Oleoyl-L-alpha-lysophosphatidic acid receptor; P2Y purinoceptor 5; Purinergic receptor 5; RB intron encoded G-protein coupled receptor

Alternative UPACC:

P43657; A4FTW9; B3KVF2; F2YGU4; O15133; Q3KPF5; Q53FA0; Q5VW44; Q7Z3S0; Q7Z3S6

Background:

Lysophosphatidic acid receptor 6, also known as Oleoyl-L-alpha-lysophosphatidic acid receptor, plays a pivotal role in the maintenance of hair growth and texture by binding to oleoyl-L-alpha-lysophosphatidic acid (LPA). Its activation involves intracellular cAMP, highlighting its significance in cellular signaling pathways. This receptor is encoded by the gene with the accession number P43657 and is alternatively named P2Y purinoceptor 5 and Purinergic receptor 5.

Therapeutic significance:

The receptor's malfunction is linked to Woolly hair autosomal recessive 1 with or without hypotrichosis and Hypotrichosis 8, diseases characterized by abnormal hair growth and texture. Understanding the role of Lysophosphatidic acid receptor 6 could open doors to potential therapeutic strategies for these hair shaft disorders, offering hope for targeted treatments.